Literature DB >> 6612272

[Lipoproteins, apolipoproteins, lipoprotein lipase, hepatic triglyceride lipase and lecithin cholesterol acyltransferase in patients with nephrotic syndrome].

C Breier, H J Lisch, H Drexel, H Braunsteiner.   

Abstract

Chronic renal disease with secondary hyperlipidemia is highly atherogenic. In uremia and patients on chronic hemodialysis there is a high incidence of atherosclerotic complications whereas the incidence of atherosclerotic disease is relatively low in the nephrotic syndrome. This is surprising, as nephrosis produces type-II hyperlipidemia, which is usually highly atherogenic. In this study 10 patients (5 male, 5 female) with a newly diagnosed nephrotic syndrome were compared to 10 controls (5 male, 5 female). As laboratory parameters, lipids, lipoproteins (VLDL, IDL, LDL, HDL2 and HDL3 by rate zonal centrifugation) and the percentage composition of the major apolipoproteins in VLDL, HDL2 and HDL3, as well as lipoprotein lipase (LPL), hepatic lipase (HTGL) and lecithin-cholesterol-acyl-transferase (LCAT) were measured. In nephrotic patients significantly higher plasma levels of cholesterol, triglycerides, phospholipids, VLDL, IDL and LDL were found, whereas HDL-chol, HDL2 and HDL3 were unchanged. LPL and HTGL were both significantly impaired, whereas LCAT was distinctly increased. The percentage composition of apolipoproteins in HDL2 and HDL3 was normal. In nephrotic VLDL, apo-AI was distinctly increased at the expense of a decrease in apo-CII, and increased LCAT was explained by the relative rise of apo-AI in nephrotic VLDL. The increase in apo-AI in VLDL is discussed as a possible reason for the low atherogenic risk of secondary hyperlipidemia in nephrotic syndrome.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6612272

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  4 in total

1.  [Reduction of post-heparin lipoprotein lipase activity by acidotic blood pH].

Authors:  C Breier; A Dzien; H J Lisch; H Braunsteiner
Journal:  Klin Wochenschr       Date:  1984-06-15

2.  Lipoprotein profiles at different stages of the nephrotic syndrome.

Authors:  U Querfeld; A Gnasso; W Haberbosch; J Augustin; K Schärer
Journal:  Eur J Pediatr       Date:  1988-04       Impact factor: 3.183

3.  Magnesium pyridoxal 5-phosphate glutamate reduces hyperlipidaemia in patients with chronic renal insufficiency.

Authors:  R Kirsten; B Heintz; K Nelson; H G Sieberth; G Oremek; J Hasford; U Speck
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  In Vitro and In Vivo (1)H-MR Spectroscopic Examination of the Renal Cell Carcinoma.

Authors:  F Süllentrop; J Hahn; D Moka
Journal:  Int J Biomed Sci       Date:  2012-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.